Skip to main content
NCBI home page
Cell Transplantation logoLink to Cell Transplantation
. 2021 Oct 26;30:09636897211053870. doi: 10.1177/09636897211053870

Sox11 Modified Tendon-Derived Stem Cells Promote the Repair of Osteonecrosis of Femoral Head

Ming Ni 1,#, Weiwei Sun 2,#, Yucong Li 3, Lingli Ding 4, Weiping Lin 3, Haiwen Peng 1, Qingyuan Zheng 1, Jingyang Sun 1, Juncheng Li 1, Hao Liu 1, Yi Yang 5, Liangliang Xu 4,✉, Guoqiang Zhang 1,✉
PMCID: PMC8552377  PMID: 34699265

Abstract

Osteonecrosis of the femoral head (ONFH) is a leading cause of mobility impairment which may lead to a total hip replacement. Recent studies have found tendon derived stem cells (TDSCs) might be an ideal cell source for musculoskeletal tissue regeneration. And our previous study has shown Sox11 could promote osteogenesis of bone marrow-derived MSCs. However, the effect of TDSCs or Sox11 over-expressing TDSCs (TDSCs-Sox11) on bone regeneration in ONFH has not been investigated. In the present study, TDSCs were infected with AAV carrying Sox11 or empty vector. We showed that Sox11 could promote the proliferation and osteogenic differentiation of TDSCs, as well as angiogenesis in vitro. The western blot analysis showed that Sox11 could activate the PI3K/Akt signaling pathway to promote osteogenesis of TDSCs. Finally, using a rabbit model of hormone-induced ONFH, our result demonstrated that local administration of TDSCs or TDSCs overexpressing Sox11 could accelerate bone regeneration in necrotic femoral heads, and TDSCs overexpressing Sox11 showed better effects. TDSCs over-expressing Sox11 might be a promising cell source for stem cell therapy to promote bone regeneration, such as ONFH, fracture, bone defect, and so on.

Keywords: osteonecrosis of the femoral head, tendon derived stem cells, Sox11, osteogenesis, angiogenesis

Introduction

Osteonecrosis of the femoral head (ONFH) is a painful disease that may lead to a total hip replacement 1 , while the etiology and pathology are not completely clarified 2 . Administration of corticosteroids is one of the most important causes leading to ONFH. Five to twenty-five percent of patients with atraumatic ONFH are caused by steroid administration 3 . The pathophysiology of steroid-associated ONFH (SAON) remains controversial. Multiple factors are involved in the process of SAON, including lipid metabolism, oxidative injury, the impaired balance between bone rebuilding and resorption and vascular impairment, and so on 4 .

Steroids can inhibit the osteogenic differentiation of bone marrow stem cells (BMSCs) while inducing differentiation of BMSCs into adipocytes, which is an important pathophysiological mechanism of SAON 5 . The abnormality of the bone marrow stem cell pool has been verified in patients with SAON clinically 6,7 , as well as in animal models 8,9 . BMSCs have been well known as promising cell sources for therapeutic use in regenerative medicine and tissue engineering. They are characterized by the multiple-lineage differentiation potentials, as well as the ability to be easily expanded ex vivo while retaining their original lineage differentiation commitment 10 –13 . Recent studies have found tendon derived stem cells (TDSCs) might be a better cell source than other cells for musculoskeletal tissue regeneration, in terms of multilineage differentiation and proliferation 14 . In addition, TDSCs also showed a better capacity to directly contribute to de novo formation in critical-sized bone defect 15 .

Sox11 is a clade of the Sox C group of the Sox (Sry-related HMG box) transcription factors. The Sox proteins are characterized by HMG box which is a highly conserved DNA binding domain. The previous study has found that Sox11 knockout mice show craniofacial and skeletal malformations, asplenia, and hypoplasia of the lung, stomach and pancreas 16 , implying that Sox11 may be associated with bone development and bone diseases. Recently, Sox11 has been identified as one of the MSC-characteristic transcription factors involved in stemness regulation by DNA microarray analysis 17 . And Knocking down Sox11 suppressed MSCs’ self-renewal capacities, reduced their osteogenic and adipogenic differentiation potential. Furthermore, our study also demonstrated that Sox11 overexpression could promote the multi-lineage differentiation potentials of MSCs, and could be used to accelerate fracture healing as well as cartilage regeneration 18,19 . However, the effect of TDSCs or TDSCs with Sox11 overexpression on bone regeneration during the progress of ONFH has not been investigated. With the potential capacities of TDSCs and the characteristic effects of Sox11, we hypothesized that the transfer of Sox11 to TDSCs using AAV might improve the repair of osteonecrosis in the rabbit model of ONFH. AAV is one of the safest viral vectors applied in clinical trials, which is supported by recent studies showing no cellular immune responses or tissue disturbance 20 –22 .

In the present study, we used recombinant AAV carrying the Sox11 gene to infect TDSCs in vitro. And mainly investigated the effects of Sox11 over-expressing on osteogenesis and angiogenesis, as well as the application of Sox11 over-expressing TDSCs to promote bone regeneration in a rabbit model of ONFH.

Materials and Methods

Isolation and Culture of Rabbit TDSCs

TDSCs were isolated from the rabbit patellar tendon by digesting with type I collagenase (3 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) as previously described 23 . The tissue enzyme solution was filtered with a 100-mm cell strainer. Single cells were collected from the filtrate, washed twice with PBS, and plated into a 100-mm culture dish at 500 cells/cm2. TDSCs were grown in LG-DMEM (Invitrogen GIBCO, New York, USA) with 10% fetal bovine serum (Invitrogen GIBCO, New York, USA) and antibiotics (penicillin 100 U/mL, streptomycin 100 g/mL) at 37°C with 5% CO2. The next day, the cells were washed with PBS to remove non-adherent cells and trypsinized when they reached 70–80% confluency. The surface antigens of TDSCs were analyzed by flow cytometry with antibodies against CD34, CD44, CD45, CD73 and CD90. Cells of passage 2-8 were used in this study.

Gene Cloning and AAV Production

The gene encoding rabbit Sox11 was amplified and cloned into an AAV viral vector by in vitro recombination. Viruses were prepared by amplification in 293 cells. The virus suspension was purified by three consecutive CsCl gradients. The viral titers were estimated by standard plaque assay. For infection of TDSCs, 5 × 105 cells were seeded into 10 cm dishes and incubated with AAV in the incubator for 12 h.

Cell Proliferation Assay

TDSCs infected with AAV-Sox11 or empty vector were plated at 2,000 cells/well in the complete culture medium in a 96-well plate and incubated at 37°C, 5% CO2. At day 3, cell proliferation was checked using the BrdU assay kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s instruction. The absorbance at 450 nm was measured and reported.

Osteogenic Differentiation

TDSCs or TDSCs-Sox11 were plated at 4 × 103 cells/cm2 in a 12-well plate and cultured in the basal medium until the cells reached confluence, respectively. They were then incubated in osteogenic induction medium (OIM), which is basal medium supplemented with 50 μM ascorbic acid (Sigma-Aldrich, USA), 1 nM dexamethasone (Sigma-Aldrich, USA) and 20 mM β-glycerolphosphate (Sigma-Aldrich, USA). At day 10, the mineralization was stained with 0.5% Alizarin red S (pH 4.1, Sigma-Aldrich, USA) for 5 min.

Quantitative Real-Time RT-PCR (qRT-PCR)

The cells were harvested and homogenized for RNA extraction with RNeasy mini kit (Qiagen, Hilden, Germany). The mRNA was reverse-transcribed to cDNA by the PrimeScript First Strand cDNA Synthesis Kit (Takara, Dalian, China). Each sample was diluted and 5 µl of total cDNA was used for amplification in reaction mixture containing Platinum SYBR Green, qPCR SuperMix-UDG ready-to-use reaction cocktail and specific primers. The expression of the target gene was normalized to that of β-actin gene. Relative gene expression was calculated with the 2- △CT formula. The sequences of the primers were shown in Supplemental Table S1.

In Vitro Tube Formation Assay

The twelve-well plates were coated with Matrigel (Becton Dickinson, USA). Then TDSCs or TDSCs-Sox11 (5000 cells/well) and HUVECs (1 × 104 cells/well) were cocultured and seeded on the 12-well plates, respectively. TDSCs (1 × 104 cells/well) alone served as blank control. DMEM and F12 basal medium (Thermo Fisher Scientific, USA) containing 2% FBS (Thermo Fisher Scientific, USA) was used. Plates were incubated at 37°C, 5% CO2 for 8 h. Bright-field images were captured for analysis of network formation.

Western Blot

Equal proteins were loaded onto 10% Tris/glycine gels for electrophoresis and then transferred to a PVDF membrane (Millipore, USA). All the antibodies used were purchased from Beijing Biosynthesis Biotechnology Co., LTD, Beijing, China. Anti-Sox11 (bs-1025 R, 1:1000), anti-VEGF (bs-1313 R, 1:1000), anti-Runx2 (bs-1134 R, 1:1000), anti-p-JNK (bs-17591 R, 1:1000), anti-JNK (bs-10562 R, 1:1000) or anti-β-actin (bs-0061 R, 1:1000) antibodies were used in this study. After washing in TBST, the membrane was incubated with horseradish peroxidase-linked secondary antibodies (anti-mouse or anti-goat) for 1 h at room temperature. Following TBST washes, protein was detected with the enhanced chemiluminescence blotting reagents (Amersham Biosciences, USA) according to the manufacturer’s instruction.

ONFH Model and Cell Transplantation

The experimental design was approved and performed following the Animal Care and Use Committee guidelines of PLA General Hospital. Eighteen 12-weeks old male New Zealand rabbits were used. Animals were anesthetized with an intravenous injection of pentobarbitone sodium. As previously described, methylprednisolone acetate (MPSL, 20 mg/kg body weight) was used to establish the steroid-induced osteonecrosis model, the physiologic saline (1ml/kg body weight) was used as control 24,25 . Four weeks after the injection, the rabbits were anesthetized and core decompression of the femoral head was performed on the right hip. The femoral head was punctured once. After then, 1 × 106 TDSCs or TDSCs-Sox11 in 100 µl PBS were delivered into the necrotic femoral head. The control group just received 100 µl PBS.

Micro-CT Examination

For microCT analysis, the femurs were scanned by vivaCT 40 (Scanco Medical AG, Bassersdorf, Switzerland) using our previously established protocols 26 . Transect scanning of the entire hip joint was performed, including the upper and lower edges. The scanning parameters were 100 kV and 220 mA.

Histology and Immunohistochemistry

Histological staining was performed as previously described 27 . Generally, the femoral heads were collected and washed in PBS, fixed in 4% paraformaldehyde, decalcified, dehydrated and embedded in paraffin. Sections were cut at a thickness of 5µm and stained with hematoxylin and eosin (H&E) after deparaffination. As for immunohistochemical (IHC) staining, endogenous peroxidase activity was quenched with 3% hydrogen peroxide at room temperature. Antigen retrieval was then performed with citrate buffer at 80°C for 10 minutes. Primary antibody against OCN (1:100; Beijing Biosynthesis Biotechnology Co., China) was used. The horseradish peroxidase (HRP)-conjugated secondary Goat anti-mouse antibody (1:100, Santa Cruz) was then added for an hour, followed by 3, 3’-diaminobenzidine tetrahydrochloride (DAKO, Glostrup, Denmark) for signal detection of OCN. Then the sections were rinsed, counterstained in hematoxylin, dehydrated, and mounted with p-xylene-bis-pyridinium bromide (DPX) permount (Sigma-Aldrich, St. Louis, MO, USA). Primary antibody was replaced with blocking solution in the negative controls. All incubation times and conditions were strictly controlled.

Data Analysis

Data were presented as mean ± SD. All the data analysis was done using SPSS (version 16.0; SPSS Inc). Two-sided t-test was used for comparison of mean values with P < 0.05 as considered statistical significance.

Results

Characterization of Rabbit TDSCs with Flow Cytometry

First, the rabbit TDSCs were isolated and cultured. At passage 2, the surface antigens of TDSCs were analyzed by flow cytometry. The result showed that rabbit TDSCs were negative for CD45 and CD34, while positive for CD44, CD90, and CD73 (Fig. 1), which was similar to the typical markers of mesenchymal stem cells as defined by the International Society for Cellular Therapy standard criteria.

Figure 1.

Figure 1.

Open in a new tab

Characterizing cell surface markers of rabbit TDSCs. The surface marker of TDSCs (passage 2) were analyzed by flow cytometry. Antibodies against CD34, CD44, CD45, CD73, and CD90 were used to stain TDSCs.

Sox11 Overexpression Increased Proliferation of TDSCs

In order to investigate the effect of TDSCs and Sox11-modified TDSCs on bone regeneration in a rabbit model of osteonecrosis, TDSCs were infected with recombinant AAV virus ( Fig. 2A ). The transfection efficiency was above 80% as estimated by the GFP signal visualized under fluorescent microscopy. Sox11 expression in TDSCs was confirmed at the protein level by western blot analysis ( Fig. 2B ). Cell proliferation analysis demonstrated that Sox11 overexpression could significantly promote the proliferation rate of TDSCs ( Fig. 2C ).

Figure 2.

Figure 2.

Open in a new tab

Sox11 promoted proliferation in TDSCs. (A) TDSCs were infected with recombinant AAV carrying Sox11 gene. (B) Detection of protein levels of Sox11 in TDSCs infected with AAV-Sox11 or empty vector by western blot analysis. The band intensity of Sox11 was quantified by Image J software. (C) Cell proliferation assay. The TDSCs infected with AAV-Sox11 or empty vector were plated at 2,000 cells/well in normal medium in a 96-well plate for 4 days, then cell proliferation was assessed using the BrdU kit. The data are expressed as mean ± SD (n = 3), *P < 0.05.

Sox11 Overexpression Promoted Osteogenesis and Angiogenesis

Next, we checked the influence of Sox11 on osteogenic differentiation and angiogenesis in TDSCs or TDSCs and HUVEC cells in vitro. It was found that Sox11 gene modification could increase the expression of osteogenic differentiation-related genes including OCN and Runx2, as well as angiogenesis-related genes such as VEGF (Fig. 3A – C ). In addition, the western blotting result showed that Runx2 and VEGF were all increased at the protein levels (Fig. 3D ). Furthermore, in vitro tube formation assays suggested that TDSCs overexpressing Sox11 stimulated the tube formation capacity of HUVEC in a 2-dimensional Matrigel culture system (Fig. 3E, F ).

Figure 3.

Figure 3.

Open in a new tab

Sox11 promoted osteogenesis and angiogenesis. (A-C) TDSCs infected with AAV-Sox11 or empty vector were subjected to osteogenic induction, the relative expression levels of OCN, Runx2 and VEGF were checked by qRT-PCR. β-actin was used as an internal control. The data are expressed as mean ± SD (n = 3), *P < 0.05. (D) Western blot analysis showing the expression of Runx2 and VEGF were increased in TDSCs-Sox11 compared to TDSCs. The band intensity of Runx2, VEGF was quantified by Image J software. The data showing here are two independent experiments. (E, F) Tube formation analysis in Matrigel coculture system in vitro. Coculture of TDSCs or TDSCs-Sox11 with HUVEC for 8 h, then the formed tube were observed and counted (n = 5). Scale bar = 50 μm. *P < 0.05.

Sox11 overexpression Enhanced Osteogenesis via PI3K/Akt Signaling Pathway

Furthermore, to clarify the underlying mechanism, TDSCs transduced with Sox11 or empty vector were treated with LY294002 which was an inhibitor of PI3K/Akt signaling pathway. It was found that the promoting effect of Sox11 overexpression on Runx2 expression in TDSCs was blocked after treated with PI3 K inhibitor for 3 days (Fig. 4A ). The Alizarin Red S staining was used to detect the formation of calcium deposits. The results demonstrated that after 2 weeks of OIM treatment, there were much fewer Alizarin Red S-positive calcium nodules formed in the LY294002 (25 μmol/L) treated TDSCs and TDSCs over-expressing Sox11 (Fig. 4B ). Western blot analysis showing the expression of Runx2, VEGF, and pAkt were increased in TDSCs-Sox11 compared to TDSCs. And after treated with PI3 K inhibitor for 3 days, p-Akt level in TDSCs/Sox11 was significantly decreased, and together with it the expression of VEGF and Runx2 also decreased, indicating that PI3K/Akt signaling pathway played an important role in promoting the effect of Sox11 on osteogenesis and angiogenesis.

Figure 4.

Figure 4.

Open in a new tab

Sox11 promoted osteogenesis via PI3K/Akt signaling pathway. (A) TDSCs infected with AAV-Sox11 or empty vector were subjected to osteogenic induction in the presence of LY290002 (25 μmol/L), the relative expression level of Runx2 was checked by qRT-PCR. β-actin was used as an internal control. The data are expressed as mean ± SD (n = 3), *P < 0.05. (B) The empty vector and AAV-Sox11 infected TDSCs were induced to undergo osteogenic differentiation for 10 days, the calcium deposits were stained with Alizarin Red S. (C, D) Total proteins were extracted from TDSCs and TDSCs-Sox11 treated with LY294002 (25 μmol/L) for 3 days or not, and then were analyzed by western blot using indicated antibodies. β-Actin was used as loading control. The band intensity of pAkt was quantified by Image J software. The experiments were repeated three times.

TDSCs Overexpressing Sox11 Enhanced bone Regeneration in the ONFH Model

To determine whether transplantation of TDSCs or TDSCs-Sox11 could enhance bone regeneration in a rabbit model of ONFH, the cells were delivered into the bone tunnel using a pipette after the core decompression procedure. The microCT analysis result showed that the femoral heads of the TDSCs and TDSCs-Sox11 groups had increased BMD and BV/TV compared with that of the PBS group (Fig. 5A - D ). But the BV/TV of femoral heads in the TDSCs group was only slightly increased compared with the PBS group (Fig. 5D ), meaning that TDSCs-Sox11 was better than TDSCs in the treatment of ONFH. In addition, the histological analysis demonstrated that the number of empty lacunae was decreased in the femur heads treated with TDSCs and TDSCs-Sox11 (Fig. 6A – D ). OCN is a specific marker of bone formation during bone turnover which characterizes the initial osteogenic differentiation. We found that the expression of OCN was consistently observed in regions associated with the localization of mesenchymal stem cells. The highest level of OCN could be observed in the TDSCs-Sox11 group (Fig. 6E – H ). In addition, the level of pAkt in TDSCs-Sox11 group was found much higher than the other groups (Fig. 6I – L ).

Figure 5.

Figure 5.

Open in a new tab

X-ray and Micro-CT analysis of femoral heads. At 4 wk after cell trans-plantation, the femoral heads were collected for micro-CT analysis. (A) Representative X-ray images of femoral heads of different groups. (B) Representative 3-dimensional images from micro-CT analysis of femoral heads. (C, D) The BMD and BV/TV (bone volume density) were analyzed by micro-CT (n = 4). *P < 0.05.

Figure 6.

Figure 6.

Open in a new tab

Histological examination of femoral heads. (A–D) Representative images of a section of femoral head in each group stained with H&E. In the TDSCs and TDSCs-Sox11 groups, the number of empty lacunae decreased. (E–H) Immunohistochemical assays of the expression of OCN in femoral head of each group. (I–L) Immunohistochemical assays of the expression of pAkt in femoral head of each group. Scale bar = 100 µm.

Discussion

In the present study, we showed that Sox11 overexpression mediated by AAV could promote the proliferation and osteogenic differentiation of TDSCs, as well as tube formation in vitro. The underlying mechanism is that Sox11 could activate the PI3K/Akt signaling pathway to promote the osteogenesis of TDSCs. Finally, using a rabbit model of hormone-induced ONFH, our result demonstrated that local administration of TDSCs overexpressing Sox11 could accelerate bone regeneration in necrotic femoral heads, as shown by the microCT and histological analysis.

MSCs have been considered as one of the most promising stem cells for cyto-therapy to treat many diseases, including fractures, cartilage defects, heart failure, and so on. The autologous bone-marrow mononuclear cells or MSCs have already been used to treat patients with the Association Research Circulation Osseous stage-I or II necrosis of the femoral head 28,29 . It is concluded that the intervention is safe and effective in delaying or avoiding femoral head collapse. Recent studies have found tendon-derived stem cells (TDSCs) might be a better cell source than BMSCs for musculoskeletal tissue regeneration, they showed better capacity to directly contribute to de novo formation in critical-sized bone defect 15 . Our previous study has also shown TDSCs could be used for tendon repair and regeneration 30 . However, the effect of TDSCs transplantation for ONFH treatment has not been studied.

ONFH is a leading cause of mobility impairment. Long-term administration of GCs (Glucocorticosteroids) is considered as one of the predominant factors resulting in ONFH 31 –33 . At present, no effective treatments have been found for ONFH 34,35 . Therefore, there is an urgent need for alternative interventions to treat ONFH and reduce patient morbidity. Although the etiology and pathology of ONFH are not completely clarified, impaired angiogenesis and osteogenesis are the two important factors involved in the process of ONFH 36 –39 . Several angiogenic and growth factors have shown promising effects on bone formation and regeneration in ONFH, including VEGF and FGF 40 –42 . In the present study, we used AAV to deliver Sox11 into MSCs. AAVs have been used in clinical studies with high efficacy and safety 43 . Recently, an intravenously dosed AAV vector delivering the SMN1 gene, Zolgensma, has been approved by FDA and successfully used in children with spinal muscular atrophy 44 . Our results showed that transplantation of Sox11-transgenic MSCs is a promising method for the treatment of ONFH. We found Sox11 could promote osteogenesis in TDSCs by activating the PI3K/Akt signaling pathway. By using the PI3K-specific inhibitor LY294002, we showed that osteogenic differentiation of TDSCs was significantly inhibited, as well as the expression levels of some specific markers such as Runx2. The PI3K/AKT pathway is involved in mediating many important cellular processes, including cell proliferation, differentiation, apoptosis, and so on. Recent studies have also found that PI3K/AKT can promote the proliferation of MSCs and inhibit their apoptosis 45,46 . Xue et al had found that Hif-1α overexpression in MSCs could improve cell viability and suppress apoptosis, in which the PI3K/AKT signaling pathway is implicated 46 . In our study, we proved that PI3K/AKT signaling pathway was also involved in the osteogenic differentiation of MSCs.

In addition, we also proved that Sox11 modified TDSCs could promote angiogenesis using tube formation assay with TDSCs and HUVEC co-culture. Sox11 has been demonstrated to be involved in neural development and organogenesis 47,48 . Some studies also showed that Sox11 was one of the most frequently upregulated genes in various cancers, including mantle cell lymphoma, epithelial ovarian cancer, breast cancer, and gastrointestinal tumors 49 –52 . The promotion of angiogenesis may be accounted for its role in tumors, as it has been shown to promote tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma 53 .

The results from histological and Micro-CT analysis clearly demonstrated that administration of TDSCs-Sox11 could restore the microstructure of the femoral head. The BMD and BV/TV of the femoral head were significantly increased by TDSCs-Sox11. And the rate of empty lacunae in ONFH was also decreased by TDSCs-Sox11. Taken together, our findings demonstrated that Sox11 could enhance angiogenesis, as well as osteogenesis via PI3K/Akt signaling pathway, and local administration of TDSCs overexpressing Sox11 could accelerate bone regeneration in necrotic femoral heads, and hopefully, the TDSCs overexpressing Sox11 might be clinically used to treat ONFH.

Supplemental Material

Supplemental Material, sj-docx-1-cll-10.1177_09636897211053870 - Sox11 Modified Tendon-Derived Stem Cells Promote the Repair of Osteonecrosis of Femoral Head
Click here for additional data file. (12.8KB, docx)

Supplemental Material, sj-docx-1-cll-10.1177_09636897211053870 for Sox11 Modified Tendon-Derived Stem Cells Promote the Repair of Osteonecrosis of Femoral Head by Ming Ni, Weiwei Sun, Yucong Li, Lingli Ding, Weiping Lin, Haiwen Peng, Qingyuan Zheng, Jingyang Sun, Juncheng Li, Hao Liu, Yi Yang, Liangliang Xu and Guoqiang Zhang in Cell Transplantation

Acknowledgments

The authors would like to thank Dr. Jing Zhang for the assistance of manuscript preparation and language editing. The work was supported by grants from the Beijing Municipal Science & Technology Commission (7192194), as well as National Natural Science Foundation of China (81472094).

Footnotes

Authors Note: Ming Ni and Guoqiang Zhang is also affiliated from Department of Orthopedics, the Fourth Medical Center, Chinese PLA General Hospital, Beijing, P.R. China.

Ethical approval: The study has been approved by the local ethics board of the Chinese People’s Liberation Army (PLA) General Hospital (Approval number S-2020-325).

Statement of Human and Animal Rights: All procedures in this study were conducted following the ‘Guide for the Care and Use of Laboratory Animals’ published by the National Academy of Science of the USA. The study has been carried out following the Animal Care and Use Committee guidelines of the Chinese Medical Association. And no human subjects were involved in this study.

Statement of Informed Consent: There are no subject in this article and informed consent is not applicable.

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD: Guoqiang Zhang Inline graphic https://orcid.org/0000-0003-2164-9506

Supplemental Material: Supplemental material for this article is available online.

References

  • 1. Mont MA, Carbone JJ, Fairbank AC. Core decompression versus nonoperative management for osteonecrosis of the hip. Clin Orthop Relat Res. 1996;(324):169–178. [DOI] [PubMed] [Google Scholar]
  • 2. Zhang Y, Sun R, Zhang L, Feng L, Liu Y. Effect of blood biochemical factors on nontraumatic necrosis of the femoral head: logistic regression analysis. Orthopade. 2017;46(9):737–743. [DOI] [PubMed] [Google Scholar]
  • 3. Powell C, Chang C, Gershwin ME. Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis. Clin Rev Allergy Immunol. 2011;41(1):102–113. [DOI] [PubMed] [Google Scholar]
  • 4. Xie XH, Wang XL, Yang HL, Zhao DW, Qin L. Steroid-associated osteonecrosis: Epidemiology, pathophysiology, animal model, prevention, and potential treatments (an overview). J Orthop Translat. 2015;3(2):58–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Chen G, Wang Q, Li Z, Yang Q, Liu Y, Du Z, Zhang G, Song Y. Circular RNA CDR1as promotes adipogenic and suppresses osteogenic differentiation of BMSCs in steroid-induced osteonecrosis of the femoral head. Bone. 2020;133:115258. [DOI] [PubMed] [Google Scholar]
  • 6. Gangji V, Toungouz M, Hauzeur JP. Stem cell therapy for osteonecrosis of the femoral head. Expert Opin Biol Ther. 2005;5(4):437–442. [DOI] [PubMed] [Google Scholar]
  • 7. Li R, Lin QX, Liang XZ, Liu GB, Tang H, Wang Y, Lu SB, Peng J. Stem cell therapy for treating osteonecrosis of the femoral head: from clinical applications to related basic research. Stem Cell Res Ther. 2018;9(1):291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Zhang G, Qin L, Sheng H, Yeung KW, Yeung HY, Cheung WH, Griffith J, Chan CW, Lee KM, Leung KS. Epimedium-derived phytoestrogen exert beneficial effect on preventing steroid-associated osteonecrosis in rabbits with inhibition of both thrombosis and lipid-deposition. Bone. 2007;40(3):685–692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Sheng HH, Zhang GG, Cheung WH, Chan CW, Wang YX, Lee KM, Wang HF, Leung KS, Qin LL. Elevated adipogenesis of marrow mesenchymal stem cells during early steroid-associated osteonecrosis development. J Orthop Surg Res. 2007;2:15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010;12:87–117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Xu L, Liu Y, Sun Y, Wang B, Xiong Y, Lin W, Wei Q, Wang H, He W, Wang B, Li G. Tissue source determines the differentiation potentials of mesenchymal stem cells: a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell Res Ther. 2017;8(1):275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Lin WP, Xu LL, Pan Q, Lin SE, Feng L, Wang B, Chen SX, Li Y, Wang HX, Li YC, Wang Y, et al. Lgr5-overexpressing mesenchymal stem cells augment fracture healing through regulation of Wnt/ERK signaling pathways and mitochondrial dynamics. Faseb Journal. 2019;33(7):8565–8577. [DOI] [PubMed] [Google Scholar]
  • 13. Lin WP, Xu LL, Zwingenberger S, Gibon E, Goodman SB, Li G. Mesenchymal stem cells homing to improve bone healing. J Orthop Trans. 2017;9:19–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Tan Q, Lui PPY, Rui YF, Wong YM. Comparison of potentials of stem cells isolated from tendon and bone marrow for musculoskeletal tissue engineering. Tissue Eng Part A. 2012;18(7-8):840–851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Kunkel N, Wagner A, Gehwolf R, Heimel P, Tempfer H, Korntner S, Augat P, Resch H, Redl H, Betz O, Bauer HC, Traweger A. Comparing the osteogenic potential of bone marrow and tendon-derived stromal cells to repair a critical-sized defect in the rat femur. J Tissue Eng Regen Med. 2017;11(7):2014–2023. [DOI] [PubMed] [Google Scholar]
  • 16. Sock E, Rettig SD, Enderich J, Bosl MR, Tamm ER, Wegner M. Gene targeting reveals a widespread role for the high-mobility-group transcription factor Sox11 in tissue remodeling. Mol Cell Biol. 2004;24(15):6635–6644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kubo H, Shimizu M, Taya Y, Kawamoto T, Michida M, Kaneko E, Igarashi A, Nishimura M, Segoshi K, Shimazu Y, Tsuji K, et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry. Genes to Cells. 2009;14(3):407–424. [DOI] [PubMed] [Google Scholar]
  • 18. Xu LL, Shunmei E, Lin S, Hou YH, Lin WP, He W, Wang HB, Li G. Sox11-modified mesenchymal stem cells accelerate cartilage defect repair in SD rats. Cell Tissue Res. 2019;376(2):247–255. [DOI] [PubMed] [Google Scholar]
  • 19. Xu LL, Huang S, Hou YH, Liu Y, Ni M, Meng FB, Wang KX, Rui YF, Jiang XH, Li G. Sox11-modified mesenchymal stem cells (MSCs) accelerate bone fracture healing: Sox11 regulates differentiation and migration of MSCs. Faseb J. 2015;29(4):1143–1152. [DOI] [PubMed] [Google Scholar]
  • 20. Ramlogan-Steel CA, Murali A, Andrzejewski S, Dhungel B, Steel JC, Layton CJ. Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations. Clin Exp Ophthalmol. 2019;47(4):521–536. [DOI] [PubMed] [Google Scholar]
  • 21. Varona R, Le-Halpere A, Campochiaro PA, Heier J, Dugel PU, Barsamian M, Purvis A, Cabrera-Salazar M, Delacono C, Mostafa N, Scaria Aet al . 3-Year interim safety profile of adeno-associated virus serotype 2-soluble variant of the vascular endothelial growth factor receptor type 1 (AAV2-sFLT01) administered by intravitreal injection in patients with neovascular age-related macular degeneration. Investig Ophthalmol Vis Sci. 2017;58(8):2321. [Google Scholar]
  • 22. Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, Anklesaria P, Birungi J, Barin B, Boaz M, Cox J, et al. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV Type 1 vaccine based on adeno-associated virus. AIDS Res Human Retroviruses. 2010;26(8):933–942. [DOI] [PubMed] [Google Scholar]
  • 23. Wu TY, Liu Y, Wang B, Sun YX, Xu J, Yuk-wai LW, Xu LL, Zhang JF, Li G. The use of cocultured mesenchymal stem cells with tendon-derived stem cells as a better cell source for tendon repair. Tissue Engineering Part A. 2016;22(19-20):1229–1240. [DOI] [PubMed] [Google Scholar]
  • 24. Yamamoto T, Irisa T, Sugioka Y, Sueishi K. Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits. Arthritis Rheum. 1997;40(11):2055–2064. [DOI] [PubMed] [Google Scholar]
  • 25. Motomura G, Yamamoto T, Irisa T, Miyanishi K, Nishida K, Iwamoto Y. Dose effects of corticosteroids on the development of osteonecrosis in rabbits. J Rheumatol. 2008;35(12):2395–2399. [DOI] [PubMed] [Google Scholar]
  • 26. He YX, Liu Z, Pan XH, Tang T, Guo BS, Zheng LZ, Xie XH, Wang XL, Lee KM, Li G, Cao YP, et al. Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model. Osteoporos Int. 2012;23(1):377–389. [DOI] [PubMed] [Google Scholar]
  • 27. Fang B, Wang D, Zheng JQ, Wei QS, Zhan DX, Liu YM, Yang XS, Wang HB, Li G, He W, Xu LL. Involvement of tumor necrosis factor alpha in steroid-associated osteonecrosis of the femoral head: friend or foe? Stem Cell Res Ther. 2019;10(1):5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Gangji V, Hauzeur JP, Matos C, De Maertelaer V, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells a pilot study. J Bone Joint Surg Am. 2004;86(6):1153–1160. [DOI] [PubMed] [Google Scholar]
  • 29. Zhao D, Cui D, Wang B, Tian F, Guo L, Yang L, Liu B, Yu X. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012;50(1):325–330. [DOI] [PubMed] [Google Scholar]
  • 30. Ni M, Rui YF, Tan Q, Liu Y, Xu LL, Chan KM, Wang Y, Li G. Engineered scaffold-free tendon tissue produced by tendon-derived stem cells. Biomaterials. 2013;34(8):2024–2037. [DOI] [PubMed] [Google Scholar]
  • 31. Zhang QK, Jin LV, Jin L. Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head. J Int Med Res. 2018;46(6):2141–2148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Wu XJ, Sun W, Tan MS. Noncoding RNAs in Steroid-Induced Osteonecrosis of the Femoral Head. Biomed Res Int. 2019;2019:8140595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Tan G, Kang PD, Pei FX. Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J. 2012;125(1):134–139. [PubMed] [Google Scholar]
  • 34. Zhao D, Liu YJ, Ma C, Gu GS, Han DF. A mini review: stem cell therapy for osteonecrosis of the femoral head and pharmacological aspects. Curr Pharm Design. 2019;25(10):1099–1104. [DOI] [PubMed] [Google Scholar]
  • 35. Zhou W, Qu M, Lv YJ, Zhu JY. New advances in stem cell therapy for osteonecrosis of the femoral head. Curr Stem Cell Res Ther. 2019;14(3):226–229. [DOI] [PubMed] [Google Scholar]
  • 36. Han J, Gao FQ, Li YJ, Ma JH, Sun W, Shi LJ, Wu XJ, Li TQ. The use of platelet-rich plasma for the treatment of osteonecrosis of the femoral head: a systematic review. Bio Res Int. 2020;2020:2642439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Saidi S, Magne D. Interleukin-33: a novel player in osteonecrosis of the femoral head? Joint Bone Spine. 2011;78(6):550–554. [DOI] [PubMed] [Google Scholar]
  • 38. Tan G, Kang PD, Pei FX. Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J (Engl). 2012;125(1):134–139. [PubMed] [Google Scholar]
  • 39. Fang B, Li Y, Chen C, Wei QS, Zheng JQ, Liu YM, He W, Lin DK, Li G, Hou YH, Xu LL. Huo Xue Tong Luo capsule ameliorates osteonecrosis of femoral head through inhibiting lncRNA-Miat. J Ethnopharmacol. 2019;238:111862. [DOI] [PubMed] [Google Scholar]
  • 40. Young S, Patel ZS, Kretlow JD, Murphy MB, Mountziaris PM, Baggett LS, Ueda H, Tabata Y, Jansen JA, Wong M, Mikos AG. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng Part A. 2009;15(9):2347–2362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Kuroda Y, Akiyama H, Kawanabe K, Tabata Y, Nakamura T. Treatment of experimental osteonecrosis of the hip in adult rabbits with a single local injection of recombinant human FGF-2 microspheres. J Bone Miner Metab. 2010;28(6):608–6016. [DOI] [PubMed] [Google Scholar]
  • 42. Wen Q, Ma L, Chen YP, Yang L, Luo W, Wang XN. Treatment of avascular necrosis of the femoral head by hepatocyte growth factor-transgenic bone marrow stromal stem cells. Gene Ther. 2008;15(23):1523–1535. [DOI] [PubMed] [Google Scholar]
  • 43. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O’Beirne J, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–2365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3–11. [DOI] [PubMed] [Google Scholar]
  • 45. Lv B, Hua T, Li F, Han J, Fang J, Xu L, Sun C, Zhang Z, Feng Z, Jiang X. Hypoxia-inducible factor 1 alpha protects mesenchymal stem cells against oxygen-glucose deprivation-induced injury via autophagy induction and PI3K/AKT/mTOR signaling pathway. Am J Transl Res. 2017;9(5):2492–2499. [PMC free article] [PubMed] [Google Scholar]
  • 46. Shi XF, Wang H, Xiao FJ, Yin Y, Xu QQ, Ge RL, Wang LS. MiRNA-486 regulates angiogenic activity and survival of mesenchymal stem cells under hypoxia through modulating Akt signal. Biochemical and Biophysical Research Communications. 2016;470(3):670–677. [DOI] [PubMed] [Google Scholar]
  • 47. Kuhlbrodt K, Herbarth B, Sock E, Enderich J, Hermans-Borgmeyer I, Wegner M. Cooperative function of POU proteins and SOX proteins in glial cells. J Biol Chem. 1998;273(26):16050–16057. [DOI] [PubMed] [Google Scholar]
  • 48. Azuma T, Ao S, Saito Y, Yano K, Seki N, Wakao H, Masuho Y, Muramatsu M. Human SOX11, an upregulated gene during the neural differentiation, has a long 3’ untranslated region. DNA Res. 1999;6(5):357–360. [DOI] [PubMed] [Google Scholar]
  • 49. Wasik AM, Lord M, Wang X, Zong F, Andersson P, Kimby E, Christensson B, Karimi M, Sander B. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression. Sci Rep. 2013;3:1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Sernbo S, Gustavsson E, Brennan DJ, Gallagher WM, Rexhepaj E, Rydnert F, Jirstrom K, Borrebaeck CAK, Ek S. The Tumour suppressor SOX11 is associated with improved cancer-specific survival among high grade epithelial ovarian cancers and is silenced in non-expressing in vitro models through reversible promoter methylation. Eur J Cancer. 2012;48:S37–S37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PH. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016;7(11):13106–13121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Xu XY, Chang XJ, Li ZH, Wang J, Deng P, Zhu XJ, Liu J, Zhang CD, Chen SC, Dai DQ. Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer. Cell Oncology. 2015;38(3):183–194. [DOI] [PubMed] [Google Scholar]
  • 53. Palomero J, Vegliante MC, Rodriguez ML, Eguileor A, Castellano G, Planas-Rigol E, Jares P, Ribera-Cortada I, Cid MC, Campo E, Amador V. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124(14):2235–2247. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material, sj-docx-1-cll-10.1177_09636897211053870 - Sox11 Modified Tendon-Derived Stem Cells Promote the Repair of Osteonecrosis of Femoral Head
Click here for additional data file. (12.8KB, docx)

Supplemental Material, sj-docx-1-cll-10.1177_09636897211053870 for Sox11 Modified Tendon-Derived Stem Cells Promote the Repair of Osteonecrosis of Femoral Head by Ming Ni, Weiwei Sun, Yucong Li, Lingli Ding, Weiping Lin, Haiwen Peng, Qingyuan Zheng, Jingyang Sun, Juncheng Li, Hao Liu, Yi Yang, Liangliang Xu and Guoqiang Zhang in Cell Transplantation

Articles from Cell Transplantation are provided here courtesy of SAGE Publications

RESOURCES